Physician profile
Ilia E Calluzzo
NPI 1073741351
$1,147.64
in general payments reported to CMS, 2019-2025
18 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $46.43 · 2021: $34.08 · 2022: $88.58 · 2023: $268 · 2024: $221 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.30 |
| Education | $159.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $283.91 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $138.90 | 2019-2022 | |
| Hologic Sales and Service, LLC | $134.02 | 2020-2024 | Myosure Tissue Removal Device, Fluent Fluid Management System, Aptima |
| Organon LLC | $129.04 | 2023-2025 | Nexplanon |
| Pfizer INC. | $91.96 | 2023-2024 | |
| Coopersurgical, INC. | $55.41 | 2021-2023 | Paragard T 380a |
| Amag Pharmaceuticals, INC. | $48.56 | 2019 | |
| Millicent US INC | $47.31 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $46.98 | 2024-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $40.00 | 2025 | |
| Smith+Nephew, INC. | $24.88 | 2019 | |
| Pharmacosmos Therapeutics INC. | $23.18 | 2025 | Monoferric |
| Mayne Pharma Commercial LLC | $19.26 | 2023 | |
| Lupin INC. | $17.73 | 2019 | |
| Abbvie INC. | $17.12 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.84 | 2019 | |
| Roche Diagnostics Corporation | $14.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilia Calluzzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.